Skip to main content
PMC home page
Nutrition Research and Practice logoLink to Nutrition Research and Practice
. 2019 Nov 22;14(2):127–133. doi: 10.4162/nrp.2020.14.2.127

Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway

Wuttipong Masraksa 1, Supita Tanasawet 2, Pilaiwanwadee Hutamekalin 3, Tulaporn Wongtawatchai 2, Wanida Sukketsiri 1,✉
PMCID: PMC7075744  PMID: 32256987

Abstract

BACKGROUND/OBJECTIVES

Non-small cell lung cancer is mostly recognized among other types of lung cancer with a poor prognosis by cause of chemotherapeutic resistance and increased metastasis. Luteolin has been found to decrease cell metastasis. However, its underlying mechanisms remain unresolved. The objective of this study was to examine the effect (and its mechanism) of luteolin on the migration and invasion of human non-small cell lung cancer A549 cells.

MATERIALS/METHODS

Cell viability was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Wound healing and transwell assays were evaluated to assess migration and invasion, respectively. Western blot analysis and immunofluorescence were further performed to investigate the role of luteolin and its mechanisms of action.

RESULTS

Administration with up to 40 µM luteolin showed no cytotoxic activity on lung cancer A549 cells or non-cancer MRC-5 cells. Additionally, luteolin at 20–40 µM significantly suppressed A549 cells' migration, invasion, and the formation of filopodia in a concentration-dependent manner at 24 h. This is similar with western blot analysis, which revealed diminished the phosphorylated focal adhesion kinase (pFAK), phosphorylated non-receptor tyrosine kinase (pSrc), Ras-related C3 botulinum toxin substrate 1 (Rac1), cell division control protein 42 (Cdc42), and Ras homolog gene family member A (RhoA) expression levels.

CONCLUSIONS

Overall, our data indicate that luteolin plays a role in controlling lung cancer cells' migration and invasion via Src/FAK and its downstream Rac1, Cdc42, and RhoA pathways. Luteolin might be considered a promising candidate for suppressing invasion and metastasis of lung cancer cells.

Keywords: Adenocarcinoma, flavonoids, luteolin, A549 cell

INTRODUCTION

Lung cancer is the third ranking cause of cancer-associated deaths worldwide, after breast and prostate cancer [1]. Epidemiological research revealed that non-small cell lung cancer (NSCLC) is the dominant type (80%) of lung cancer, and its prognosis remains notably poor with a 5-year survival rate below 20% [2]. Ongoing therapies for NSCLC, including surgery, radiotherapy and chemotherapy, have a limited effect on patient survival, and the associated high toxicities include neutropenia, peripheral neuropathy, nausea and vomiting, and nephrotoxicity [3]. Therefore, novel cancer therapeutic agents with high efficacy and low toxicity or less severe side effects are desired.

Metastasis is a multistep complex process, in which local invasion of the primary tumor is important for the initiation of metastasis. The machinery of cell migration is associated with several complicated steps asociating the stimulation of various important regulatory proteins. Rho GTPase proteins, such as Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division control protein 42 (Cdc42), which was shown to trigger actin polymerization and reorganization, occurring in the filopodia and the lamellipodia protrusion [4,5]. Simultaneously, the active structure of Ras homolog gene family, member A (RhoA) activates the actin-myosin shrinkage [6]. A previous study has established that Rho GTPase family migratory proteins are stimulated via the focal adhesion kinase (FAK) and a nonreceptor tyrosine kinase (Src) pathways [7]. Besides, FAK and Src activation has been established in highly metastatic cancer cells [8,9,10]. It has been revealed that lung cancer cells' migration and invasion are mediated due to the stimulation of FAK and Src pathways [11]. Accordingly, inhibiting these proteins' activities block the mobility and metastasis of numerous cancer cells [12,13].

Luteolin (3′,4′,5,7-tetrahydroxyflavone; Fig. 1), a natural flavonoid compound, is generally found at high concentration in fruits, vegetables and medicinal herbs [14]. Luteolin obtains various pharmacological effects such as anti-oxidant, anti-cancer, anti-inflammation, immune regulation and cardioprotection [15,16,17]. Many studies have revealed that luteolin has anti-tumor activity against various types of cancer [18,19,20]. A number of studies have found that luteolin has a potent effect on human NSCLC A549 cell proliferation by activating cell death and inhibiting cell migration [21,22]. Previous report revealed that luteolin inhibit cancer cell migration is correlated with suppression of the activation of phosphorylated insulin-like growth factor-1 receptor (p-IGF-1R), phosphoinositide 3-kinase (PI3K), protein kinase B (Akt) and mammalian target of rapamycin (mTOR) signaling pathway [23]. Nevertheless, the mechanisms of action of luteolin in suppressing cancer cells' migration and invasion remain unresolved. Especially, the expression of FAK, Src and Rho GTPase proteins, such as Rac1, Cdc42 and RhoA, in human lung cancer cells has not been identified. Therefore, this study aimed to investigate whether luteolin is able to restrain cell migration and invasion by human NSCLC A549 cells; and whether this occurs by suppressing the FAK, Src as well as Rac1, Cdc42 and RhoA pathways, relevant to filopodia formation.

Fig. 1. Chemical structure of luteolin.

Fig. 1

Open in a new tab

MATERIALS AND METHODS

Chemicals and reagents

Luteolin, dimethysulfoxide (DMSO), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), bovine serum albumin (BSA), phenylmethylsulfonyl fluoride, and protease inhibitor cocktail were obtained from Sigma Chemical, Inc. (St. Louis, MO, USA). Antibodies for FAK (Santa Cruz Biotechnology, CA, USA), pFAK (Santa Cruz Biotechnology, CA, USA), Src (Abcam, Cambridge, UK), pSrc (Abcam, Cambridge, UK), Rac1 (Merck, Kenilworth, USA), RhoA (Abcam, Cambridge, UK), Cdc42 (Merck, Kenilworth, USA), β-actin (Thermo Scienetific, Waltham, MA, USA), and peroxidase conjugated secondary antibodies (Thermo Scienetific, Waltham, MA, USA) were purchased. Lysis buffer and chemiluminescent substrate were obtained from Thermo Scientific (Supersignal West Pico; Pierce, USA).

Cell cultures

MRC-5 human lung fibroblast cells and A549 human lung carcinoma cells were received from the CLS cell lines service (Eppelheim, Germany). The lung cancer A549 cells were grown in DMEM/Ham-F12 medium, whereas MRC-5 cells were cultured in DMEM medium. Both of cell types were kept in a 5% CO2 humidified incubator at 37℃. The media were enriched with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 IU/mL penicillin, and 100 µg/mL streptomycin (Gibco, MD, USA). Both types of cells were sub-cultured using trypsin-EDTA at 80–90% confluence.

Cell viability assay

MTT colorimetric assay was used for examination of cell viability. A549 cells and MRC-5 cells were seeded at 1 × 104 cells/well and incubated for 24 h in a 96-well plate for cell attachment. Both types of cells were then administered with various concentrations of luteolin (0–80 µM) for 24 h in order to investigate cell viability. Following the 24 h of luteolin administration, the medium was discarded and the cells were incubated with MTT solution for 2 h at 37℃. Formazan product was solubilized with DMSO, and the intensity was assessed using a microplate reader at 570 nm (Biotek, Winooski, VT, USA). The experimental results are presented as the percentage of cell viability comparative to the non treatment control.

Nuclear staining assay

A549 cells (5 × 104 cells/well) were grown in 24-well plates, and incubated overnight. A549 cells were administered with luteolin at different concentrations (0, 10, 20 and 40 µM) at 37℃ for 24 h. Hoechst 33342 (10 µg/mL) was applied to the cells for 30 min at 37℃, as described previously [24]. The apoptotic cells, which have the chromatin condensation and fragmented nuclei, were observed by utilizing a fluorescence microscope (Olympus IX73; 20×) supplied with a DP73 digital camera system (Olympus, Tokyo, Japan).

Wound healing assay

Cells were grown until they reached 90–95% confluence in 6-well plates. A sterile 200 µL pipette tip was applied to make a cross-shaped wound. Then, the cells were gently rinsed with PBS. Subsequently, the cells were cultivated for 0, 24 and 48 h. Cells that migrated to the wounded area were imaged. The percentage of wound closure was also evaluated.

Cell invasion assay

A trans-well chamber (Corning, NY, USA) was used for an invasion assay. Prior to seeding the cells in the upper chamber, the membrane (8 µm pore size) was applied with matrigel (0.5%) for 12 h at 37℃. After 24 h, A549 cells (5 × 104 cells/well) were grown in the upper chamber supplied with serum-free medium. The lower chamber was supplied with complete medium containing FBS (10%). After that, the unpenetrated cells were lightly detached with a cotton swab in the upper chamber, whereas the penetrated cells that had invaded the lower compartment were fixed with paraformaldehyde (PFA) (4%) for 10 min and stained with Hoechst 33342 (10 µg/mL) for 30 min (N = 4). The cells were observed and photographed using a fluorescence microscope (Olympus IX73; 20×). Finally, the invading cells were counted as (the number of invaded cells treated with luteolin/the number of invaded cells of non-treated cells) × 100.

Filopodia evaluation assay

Filopodia was evaluated by phalloidin-rhodamine staining assay as reported previously [25]. Phalloidin rhodamine was applied to specific binding with the polymerized form of actin (F-actin) in the cells. Briefly, luteolin-treated A549 cells were fixed with 4% PFA and permeabilized for 5 min with 0.1% Triton-X in PBS. Subsequently, the cells were washed and blocked for non-specific binding with BSA (0.2%) for 1 h, followed by incubation with a phalloidin rhodamine for 30 min. Cell morphological alterations were observed and photographed using a fluorescence microscope (Olympus IX73; 40×). The filopodia counts are reported as (number of filopodia/number of cells) × 100.

Western blot analysis

After treatment with luteolin to A549 cells, lysis buffer and protease inhibitor cocktail were applied for 30 min on ice. The cellular lysates were collected and the content of protein was detected using a Bradford reagent (Bio-Rad, USA). The 75 µg of protein from each sample were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and moved to nitrocellulose membranes (0.45 µM, Merck). The membranes were blocked with blocking solution for 2 h, and were then applied with the appropriate primary antibodies overnight at 4℃. Then, the membranes were washed and incubated with horseradish peroxidase-linked secondary antibodies for 1 h at room temperature. Eventually, the protein bands were evaluated using an enhanced chemiluminescence substrate.

Statistical analysis

Experimental data of four independent experiments are displayed as mean ± standard error of the mean (SEM). The data analysis was carried out by R program (R Core Team, 2014). ANOVA (analysis of variance), followed by individual comparisons with Tukey's post-hoc test, was performed to analyze differences between multiple groups. Statistical significance required P < 0.05.

RESULTS

Effect of luteolin on cell viability in human lung cancer A549 cells

To determine an appropriate dose of luteolin for use in further experiments, we determined the cell viability of A549 cells treated with luteolin. The cells were administered with luteolin at different dosages (0–80 µM) for 24 h and cell viability was then investigated. Fig. 2A shows that significant cytotoxic effects of luteolin were found only at the highest 80 µM concentration, whereas it did not affect normal MRC-5 lung fibroblasts. Morphological examination of cell death after treatment with luteolin was done by both phase contrast microscopy and nuclei staining with Hoechst. Phase contrast microscopy demonstrated that luteolin induced A549 cell deaths in comparison to the untreated control (Fig. 2B). Distinctive morphological alterations, including the loss of cell processes and cell contact, more rounded morphology, and reduction of viable cells were observed with 40 µM luteolin treatments. In addition, nuclei staining indicated that luteolin at 0–20 µM did not induce apoptosis of cells. However, 40 µM luteolin treatments significantly induced apoptotic cells, called by condensed and/or fragmented nuclei (Fig. 2B and 2C).

Fig. 2. Cytotoxic activity of luteolin against A549 cells. (A) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after 24 h treatment.

Fig. 2

Open in a new tab

(B) Phase contrast microscopy and Hoechst 33342 staining after 24 h treatment (scale bar = 100 µm). White arrowheads indicate the apoptotic cells. (C) The number of apoptotic cells. Data are shown as mean ± SEM from four independent experiments. *P < 0.001 versus the control.

Luteolin attenuates migration and invasion of lung cancer A549 cells

Wound healing assay was carried out to evaluate the effects of luteolin on lung cancer cell migration. A549 cells were administered with luteolin at the concentrations 0, 10, 20 and 40 µM for 0, 24 and 48 h. Fig. 3A and 3B showed that luteolin at the concentrations of 20 and 40 µM significantly suppressed the migration of cell across the wound space at 24 and 48 h, compared to the untreated control. We further determined the anti-invasive activity of luteolin against A549 cells. Our results indicated that luteolin at the concentrations 10, 20 and 40 µM was able to significantly diminish the invading cells across the matrix and transwell membrane at 24 h, in a concentrationdependent manner, compared to the untreated control (Fig. 4A and 4B).

Fig. 3. Luteolin inhibits lung cancer cell migration.

Fig. 3

Open in a new tab

(A) The migration into wound area was determined from comparison to the control. (B) The cell migration was visualized via phase contrast microscopy (scale bar = 100 µm). Data are expressed as mean ± SEM from four independent experiments. The differences between groups were evaluated by one-way ANOVA. §P < 0.01 compared to control. #P < 0.01 compared to time 0.

Fig. 4. Luteolin inhibits lung cancer cell invasion.

Fig. 4

Open in a new tab

(A) The percentage of invaded cells/field were measured. (B) The cell invasion was observed by using Hoechst 33342 staining (scale bar = 100 µm). Data are expressed as mean ± SEM from four independent experiments. The differences between groups were evaluated by one-way ANOVA. *P < 0.001 compared to control.

Luteolin attenuates filopodia formation of lung cancer A549 cells

The cellular protrusions known as filopodia are a principal marker of motile cells. Cancer cells display formation of filopodia during migration and invasion [5,26]. Accordingly, we observed the numbers of filopodia formed for response to luteolin treatment. The A549 cells were administered with various concentrations of luteolin (0–40 µM) for 24 h, after which phalloidin-rhodamine staining assay was used to evaluate the production of filopodia. Fig. 5A and 5B show that A549 cells treated with luteolin exhibited significantly reduced numbers of filopodia in a concentration-dependent manner, when compared to the untreated control.

Fig. 5. Effects of luteolin on filopodia formation.

Fig. 5

Open in a new tab

(A) A549 cells were stained with phalloidin-rhodamine (scale bar = 50 µm). White arrowheads indicate the filopodia. (B) Filopodia counts per cell after treatment with various concentrations of luteolin. Data are expressed as mean ± SEM from four independent experiments. The differences between groups were evaluated by one-way ANOVA. *P < 0.001 compared to control.

Luteolin suppresses migration-related protein expression in lung cancer A549 cells

To clarify the mechanisms by which luteolin suppressed the cancer migration and invasion of cell, the expression levels of proteins associated with cell migration were assessed. The A549 cells were exposed with or without luteolin (10–40 µM) for 24 h. Protein expression of FAK, activated FAK (phosphorylated FAK at Tyr-397), Src, and activated Src (phosphorylated Src at Ser416), were investigated from western blots. Fig. 6A and 6B shows that treatment of A549 cells with luteolin (20–40 µM) substantially suppressed the expression of activated FAK and activated Src, while the non-activated forms of FAK and Src proteins were not affected. Moreover, the expression levels of Rac1, Cdc42 and RhoA were tightly related to cancer cell migration. We further evaluated at the protein levels by examined the expression of Rac1, Cdc42 and RhoA. The results show that luteolin (20–40 µM) significantly down-regulated Rac1, Cdc42 and RhoA expression in A549 non-small cell lung cancer cells (Fig. 6C and 6D). These results imply that luteolin possibly regulated cell migration by suppressing FAK and Src upstream pathways, and Rac1, Cdc42 and RhoA downstream pathway.

Fig. 6. Luteolin inhibits focal adhesion kinase (FAK), non-receptor tyrosine kinase (Src), Ras-related C3 botulinum toxin substrate 1 (Rac1), cell division control protein 42 (Cdc42), and Ras homolog gene family member A (RhoA) protein expressions.

Fig. 6

Open in a new tab

(A) and (B) Western blots and the relative level of FAK and Src in A549 cells after treatment with luteolin for 24 h. (C) and (D) Western blots and the relative level of Rac1, Cdc42 and RhoA in A549 cells after treatment with luteolin for 24 h. Data are shown as mean ± SEM from four independent experiments, §P < 0.01 compared to control.

DISCUSSION

Flavonoids, such as luteolin, have shown potential to be developed to anticancer treatments [27]. Luteolin, 3,4,5,7-tetrahydroxy flavone, has been noted to have a strong anticancer effect against lung cancer cells [21,22]. In order to obtain further information concerning the anti-cancer activities of luteolin compound, its suppressive activity on the cancer cells migration and invasion were investigated in this study. Previous studies have reported that luteolin possesses cytotoxic efficacy against many human cancer cell lines, including esophageal carcinoma EC1 and KYSE450 cell lines, human gastric cancer MKN45 and BGC823 cell lines, human cervical cancer HeLa cell line, and human lung carcinoma H520 and H661 cell lines, with the respective IC50 values at 24 h ranging from 5 to 80 µM [28,29,30]. In this study, we determined the cytotoxic properties of luteolin on human non-small cell lung cancer (NSCLC) A549 cells, and found that luteolin has an IC50 of 78.86 µM at 24 h, while it did not show substantial toxicity against normal human lung fibroblast MRC-5 cells.

Lung cancer is among primary causes of cancer-associated mortality worldwide, in both men and women, partly because of active metastasis by transmiting malignant cells to other parts of the body [31]. Among multiple processes involved in metastasis, cancer cell migration has been identified as a critical indication of metastasis throughout the body [31]. Several studies reported the anti-migration and anti-invasion potentials of luteolin on breast cancer and glioblastoma cell lines [21,32]. Also, the suppression of migration and invasion by luteolin has been evaluated in lung cancer cells [21] but the mechanisms still undefined. This present study demonstrated that luteolin significantly blocked lung cancer cells' migration and invasion in a concentration-dependent manner. Therefore, our results illustrate that luteolin inhibits the invasion and migration of A549 cells by hindering filopodia formation, and down-regulating the expression of focal adhesion kinase (FAK)-non-receptor tyrosine kinase (Src) signaling cascade in motility down-stream regulator proteins, including Ras-related C3 botulinum toxin substrate 1 (Rac1), cell division control protein 42 (Cdc42), and Ras homolog gene family member A (RhoA).

A recent study demonstrated the FAK/Src signaling as a target pathway to inhibit for preventing cancer metastasis [12]. Additionally, the expression levels of FAK and Src were reported to be upregulated in NSCLC tissues, when compared with normal lung tissue, and strongly correlated with metastatic stage of the disease [33,34,35]. The dual kinase complex FAK-Src negotiated signaling pathway is the remarkably critical signaling pathways related to metastasis from many tumors types [36,37,38]. FAK phosphorylation at Y397 is important for its stimulation and Src recruitment [39] and critical for cell migration [40,41]. It has also been reported that luteolin diminished the phosphorylation of FAK at Y397 and decreased phosphorylated Src at Y416 in lung cancer A549 cell lines, while Y416 phosphorylation preserves Src in an active form and stimulates Src enlistment to FAK [42,43]. Recent studies have established FAK-Src signaling deregulation in many tumor types [12,42]. Lung tumors with increased activity of FAK and Src have also increased metastatic potential [34,35]. Consequently, the suppression of FAK-Src signaling by luteolin may decrease the ability of lung cancer cells to migrate and invade.

The migration of cells is mainly forced by F-actin polymerization, focal adhesion complexes' development at the leading border, depolymerization of F-actin, and focal adhesion complexes' disassembly at the rear end of the cell [44]. The formation of cellular protrusions is an important step in triggering cell motility [5,26]. FAK-Src possesses the capacity to mediate transformations of the cell, including uncontrolled cell division, and it stimulates several downstream targets such as Rac1, Cdc42 and RhoA pathways [26,45,46]. Our results show that luteolin inhibits filopodia formation and correlates with the protein expression inhibition of downstream signaling pathways (Rac1, Cdc42 and RhoA) in A549 cells. RhoA involves cell to cell or cell to extracellular matrix communication by activating the changes of cytoskeleton. Rac1 affects membrane ruffling by changing the polymerization of actin and Cdc42, involved in the development of filopodia, via triggering assembly of F-actin filaments. In this study, we demonstrated that luteolin reduced the quantity of F-actin fibers and disturbed development of the long stress fiber that traverses the cell body. This modification in actin cytoskeleton is likely associated with diminished migration and invasion, which correlated with down-regulated expression of RhoA, Rac1, and Cdc42. This might damage the contraction and retraction of cell body at the rear end of the cell, and restrict development of protrusions at the leading border.

In conclusion, luteolin treatment restrict the migration of non-small cell lung cancer cells in vitro by abolishing the development of focal adhesion, and by inhibiting FAK-Src signaling. Luteolin also changes the expression of Rac1, Cdc42 and RhoA that are regulating proteins of actin cytoskeleton and of cell migration (Fig. 7). Further investigations are needed to validate our conclusion in an animal study and to develop luteolin for lung cancer chemotherapeutic application. Overall, luteolin appears a promising candidate for ancillary treatment to prevent tumor cell metastasis.

ACKNOWLEDGMENTS

The study was supported by the grant from the General Project and Invention of Prince of Songkla University (no. SCI610456S) and Faculty of Science Research Fund (Contract no. 1-2560-02-004), Prince of Songkla University, Songkhla, Thailand. The authors are thankful for Publication Clinic of Prince of Songkla University and Associate Professor Seppo Karrila, Ph.D. for providing assistance in proofreading on the manuscript.

Footnotes

The study was supported by the grant from the General Project and Invention of Prince of Songkla University (no. SCI610456S) and Faculty of Science Research Fund (Contract no. 1-2560-02-004), Prince of Songkla University, Songkhla, Thailand.

CONFLICT OF INTEREST: The authors declare no potential conflicts of interests.

References

  • 1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
  • 2.Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–367. doi: 10.4065/83.3.355. [DOI] [PubMed] [Google Scholar]
  • 3.Artal Cortés Á, Calera Urquizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res. 2015;4:191–197. doi: 10.3978/j.issn.2218-6751.2014.06.01. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509–514. doi: 10.1126/science.279.5350.509. [DOI] [PubMed] [Google Scholar]
  • 5.Ridley AJ. Rho GTPases and cell migration. J Cell Sci. 2001;114:2713–2722. doi: 10.1242/jcs.114.15.2713. [DOI] [PubMed] [Google Scholar]
  • 6.Iden S, Collard JG. Crosstalk between small GTPases and polarity proteins in cell polarization. Nat Rev Mol Cell Biol. 2008;9:846–859. doi: 10.1038/nrm2521. [DOI] [PubMed] [Google Scholar]
  • 7.Tomar A, Schlaepfer DD. Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility. Curr Opin Cell Biol. 2009;21:676–683. doi: 10.1016/j.ceb.2009.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–149. doi: 10.1016/j.pharmthera.2014.10.001. [DOI] [PubMed] [Google Scholar]
  • 9.Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4:470–480. doi: 10.1038/nrc1366. [DOI] [PubMed] [Google Scholar]
  • 10.Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012;33:122–128. doi: 10.1016/j.tips.2011.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Park GB, Kim D. Cigarette smoke-induced EGFR activation promotes epithelial mesenchymal migration of human retinal pigment epithelial cells through regulation of the FAK-mediated Syk/Src pathway. Mol Med Rep. 2018;17:3563–3574. doi: 10.3892/mmr.2017.8355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–523. doi: 10.1016/j.ceb.2006.08.011. [DOI] [PubMed] [Google Scholar]
  • 13.Prateep A, Sumkhemthong S, Karnsomwan W, De-Eknamkul W, Chamni S, Chanvorachote P, Chaotham C. Avicequinone B sensitizes anoikis in human lung cancer cells. J Biomed Sci. 2018;25:32. doi: 10.1186/s12929-018-0435-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Miean KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem. 2001;49:3106–3112. doi: 10.1021/jf000892m. [DOI] [PubMed] [Google Scholar]
  • 15.Imran M, Rauf A, Abu-Izneid T, Nadeem M, Shariati MA, Khan IA, Imran A, Orhan IE, Rizwan M, Atif M, Gondal TA, Mubarak MS. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed Pharmacother. 2019;112:108612. doi: 10.1016/j.biopha.2019.108612. [DOI] [PubMed] [Google Scholar]
  • 16.López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009;9:31–59. doi: 10.2174/138955709787001712. [DOI] [PubMed] [Google Scholar]
  • 17.Xu T, Li D, Jiang D. Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion. Nutrients. 2012;4:2008–2019. doi: 10.3390/nu4122008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther. 2001;90:157–177. doi: 10.1016/s0163-7258(01)00137-1. [DOI] [PubMed] [Google Scholar]
  • 19.Martin KR. Targeting apoptosis with dietary bioactive agents. Exp Biol Med (Maywood) 2006;231:117–129. doi: 10.1177/153537020623100201. [DOI] [PubMed] [Google Scholar]
  • 20.Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a review. Crit Rev Food Sci Nutr. 2018;58:1428–1447. doi: 10.1080/10408398.2016.1263597. [DOI] [PubMed] [Google Scholar]
  • 21.Chen KC, Chen CY, Lin CR, Yang TY, Chen TH, Wu LC, Wu CC. Luteolin attenuates TGF-β1-induced epithelial-mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt-NF-κB-Snail pathway. Life Sci. 2013;93:924–933. doi: 10.1016/j.lfs.2013.10.004. [DOI] [PubMed] [Google Scholar]
  • 22.Ma L, Peng H, Li K, Zhao R, Li L, Yu Y, Wang X, Han Z. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis. Mol Med Rep. 2015;12:4196–4202. doi: 10.3892/mmr.2015.3956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang Q, Wang H, Jia Y, Ding H, Zhang L, Pan H. Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p-IGF-1R/PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2017;14:3545–3551. doi: 10.3892/ol.2017.6643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sukketsiri W, Sawangjaroen K, Tanasawet S. Anti-apoptotic effects of phyllanthin against alcohol induced liver cell death. Trop J Pharm Res. 2016;5:981–988. [Google Scholar]
  • 25.Singkhorn S, Tantisira MH, Tanasawet S, Hutamekalin P, Wongtawatchai T, Sukketsiri W. Induction of keratinocyte migration by ECa 233 is mediated through FAK/Akt, ERK, and p38 MAPK signaling. Phytother Res. 2018;32:1397–1403. doi: 10.1002/ptr.6075. [DOI] [PubMed] [Google Scholar]
  • 26.Sit ST, Manser E. Rho GTPases and their role in organizing the actin cytoskeleton. J Cell Sci. 2011;124:679–683. doi: 10.1242/jcs.064964. [DOI] [PubMed] [Google Scholar]
  • 27.Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8:634–646. doi: 10.2174/156800908786241050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chen P, Zhang JY, Sha BB, Ma YE, Hu T, Ma YC, Sun H, Shi JX, Dong ZM, Li P. Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450. Oncotarget. 2017;8:27471–27480. doi: 10.18632/oncotarget.15832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Cherng JM, Shieh DE, Chiang W, Chang MY, Chiang LC. Chemopreventive effects of minor dietary constituents in common foods on human cancer cells. Biosci Biotechnol Biochem. 2007;71:1500–1504. doi: 10.1271/bbb.70008. [DOI] [PubMed] [Google Scholar]
  • 30.Pu Y, Zhang T, Wang J, Mao Z, Duan B, Long Y, Xue F, Liu D, Liu S, Gao Z. Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs. J Cancer. 2018;9:3669–3675. doi: 10.7150/jca.27183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594. doi: 10.4065/83.5.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Cook MT. Mechanism of metastasis suppression by luteolin in breast cancer. Breast Cancer (Dove Med Press) 2018;10:89–100. doi: 10.2147/BCTT.S144202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M, Di Giulio AM, Gorio A, Bosari S. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer. 2006;53:263–271. doi: 10.1016/j.lungcan.2006.06.001. [DOI] [PubMed] [Google Scholar]
  • 34.Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP, Bai J. Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2013;139:429–435. doi: 10.1007/s00432-012-1342-8. [DOI] [PubMed] [Google Scholar]
  • 35.Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer. 1992;28:372–377. doi: 10.1016/s0959-8049(05)80056-5. [DOI] [PubMed] [Google Scholar]
  • 36.Bolós V, Gasent JM, López-Tarruella S, Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther. 2010;3:83–97. doi: 10.2147/ott.s6909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 2004;14:241–249. doi: 10.1016/j.tcb.2004.03.011. [DOI] [PubMed] [Google Scholar]
  • 38.Gu MM, Gao D, Yao PA, Yu L, Yang XD, Xing CG, Zhou J, Shang ZF, Li M. p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma. Cancer Sci. 2018;109:3783–3793. doi: 10.1111/cas.13818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994;14:1680–1688. doi: 10.1128/mcb.14.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Chen M, Chen SC, Pallen CJ. Integrin-induced tyrosine phosphorylation of protein-tyrosine phosphatase-alpha is required for cytoskeletal reorganization and cell migration. J Biol Chem. 2006;281:11972–11980. doi: 10.1074/jbc.M600561200. [DOI] [PubMed] [Google Scholar]
  • 41.Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KS, Cheresh DA, Schlaepfer DD. Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003;160:753–767. doi: 10.1083/jcb.200212114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Chikara S, Lindsey K, Borowicz P, Christofidou-Solomidou M, Reindl KM. Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines. BMC Complement Altern Med. 2017;17:30. doi: 10.1186/s12906-016-1512-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sandilands E, Frame MC. Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol. 2008;18:322–329. doi: 10.1016/j.tcb.2008.05.004. [DOI] [PubMed] [Google Scholar]
  • 44.Gardel ML, Schneider IC, Aratyn-Schaus Y, Waterman CM. Mechanical integration of actin and adhesion dynamics in cell migration. Annu Rev Cell Dev Biol. 2010;26:315–333. doi: 10.1146/annurev.cellbio.011209.122036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6:587–595. doi: 10.1038/nrclinonc.2009.129. [DOI] [PubMed] [Google Scholar]
  • 46.Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–358. doi: 10.1023/a:1023772912750. [DOI] [PubMed] [Google Scholar]

Articles from Nutrition Research and Practice are provided here courtesy of Korean Society of Community Nutrition and the Korean Nutrition Society

RESOURCES